Skip to main content

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

Active, not recruiting · Phase 3 · NCT06260722

Conditions: Diabetes Mellitus, Type 2

At a glance

Research payments reported, 2025
$7.0M
U.S. investigators named
49
Sites paid
50
Planned or actual enrollment
1,250

About the trial

Sponsor
Eli Lilly and Company
Tested
Retatrutide (drug), Semaglutide (drug)
Dates
Started 2024-02-21; completion 2027-02
Results posted
Not yet

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.

From ClinicalTrials.gov, last updated 2026-09-28. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $7.0M in research payments for this study in 2025 (97 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • New Age Medical Research Corp $644,199
  • Gcm Medical Group Psc $627,254
  • Texas Valley Clinical Research LLC $619,360
  • Palm Research Center Inc $382,529
  • Juno Research LLC $264,187
  • Long Beach Research Institute LLC $252,111
  • Medrasa Clinical Research LLC $232,045
  • Central State Research $226,987
  • Arcturus Healthcare PLC, Troy Internal $225,114
  • Valley Clinical Trials Inc $223,694
  • South Broward Research, LLC $211,814
  • Advanced Clinical Research LLC $207,627
  • Southern Endocrinology Associates PA $184,973
  • Alliance for Multispecialty Research Lls $158,252
  • Central Washington Health Services $158,049
  • North Georgia Clinical Research $157,652
  • Corvallis Clinic PC $152,781
  • Remington-Davis, Inc. $152,535
  • Medication Management LLC $149,530
  • Pacific Diabetes and Endocrine Center $149,285
  • Neccr Prima Care Research LLC $149,229
  • Arrow Clinical Trials LLC $148,122
  • Nyc Research Inc $144,650
  • Clincial Research of Central Florida $130,752
  • Velocity Clinical Research Inc $127,569
  • Deaconess Clinic Inc $119,336
  • Brigham and Women's Hospital, MA $111,960
  • Thomas Jefferson University $101,799
  • Consano Clinical Research LLC $92,517
  • Neighborhood Healthcare $78,124
  • Valley Institute of Research LLC $75,763
  • Medstar Health Research Institute $72,836
  • Herman Clinical Research LLC $60,123
  • Regents of the University of Colorado $58,125
  • Ima Evaluations LLC DBA Ima Clinical Research $44,227
  • Rancho Cucamonga Clinical Research $30,649
  • University of Alabama Hospital, AL $19,029
  • Cleveland Clinic, OH $1,470
  • Wenatchee Valley Hospital $957
  • Deaconess Hospital Inc, IN $944
  • Pharmquest LLC $821
  • University of Colorado Barbara Davis Center - Pediatric Clinic $623
  • Dallas Diabetes and Endo Research Center PA $621
  • Medex Healthcare Research Inc $570
  • Intend Research LLC $405
  • Clinical Research of Central Florida $284
  • Rocky Mountain Clinical Research LLC $65
  • M Super Holdings LLC Ima Evaluations LLC $65
  • Lightship Inc $9
  • Premier Research Institute $1

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.